Add BrightSurf on Google Email

Search results for “Oncology”

1,000+ results for "Oncology"

Researchers show increased survival rate in prostate cancer patients with addition of hormone therapy treatments

A meta-analysis published in The Lancet Oncology reveals that men with intermediate- and high-risk prostate cancer experience improved overall survival with the addition of hormone therapy to radiotherapy. The study found prolonged adjuvant hormone therapy benefits men, while neoadjuvant hormone therapy did not.

SourceUniversity Hospitals Cleveland Medical Center·JournalThe Lancet Oncology·TypeMeta-analysis·DateJan 18, 2022

ASTRO issues clinical guideline on external beam radiation therapy for primary liver cancers

The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline outlining the use of external beam radiation therapy (EBRT) to treat adult patients with primary liver cancers. The guidelines emphasize multidisciplinary care and provide evidence-based recommendations on indications, dosing, techniques, and trea...

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateJan 12, 2022

NRG Oncology trial data concludes paclitaxel and carboplatin should be considered the standard of care as first-line treatment for women with uterine carcinosarcoma

The NRG Oncology GOG 0261 trial demonstrated that paclitaxel and carboplatin is a non-inferior alternative to paclitaxel and ifosfamide for treating women with uterine carcinosarcoma. This regimen offers improved progression-free survival and overall survival compared to the current standard of care.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJan 11, 2022

Study: Although they tend to be diagnosed with higher-risk prostate cancer, Black men undergoing radiation therapy have better outcomes than white men

A meta-analysis of seven randomized trials found that Black men with localized prostate cancer had lower recurrence, metastasis, and mortality rates compared to white men. The study challenges the common belief that Black men with prostate cancer have a worse prognosis.

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·TypeMeta-analysis·DateDec 29, 2021

City of Hope researchers help find improved treatment options for patients with advanced colorectal cancer

A Phase 2 clinical trial showed sotorasib can shrink tumors and achieve disease control in heavily pretreated patients with advanced colorectal cancer. The study results exceeded the historic benefits linked to approved therapies, offering new hope for a population with limited treatment options.

SourceCity of Hope·JournalThe Lancet Oncology·TypeRandomized controlled/clinical trial·DateDec 14, 2021

Australian GenesisCare doctors co-author world-first international consensus statement on Cardio-Oncology

The international consensus statement provides critical recommendations for the cardiovascular management and follow-up of patients undergoing radiation therapy. The paper highlights the need to identify and address cardiovascular risk factors to prevent cardiotoxicity, emphasizing the importance of regular screening and treatment for ...

SourceGenesisCare·JournalJournal of the American College of Cardiology·TypeLiterature review·DateDec 13, 2021

Serial radiation therapy is safe and effective as alternative treatment to systemic therapy for kidney cancer

Researchers at MD Anderson Cancer Center reported that serial stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic renal cell carcinoma. The study showed promising results, with a median progression-free survival of 22.7 months and minimal toxicity.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet Oncology·DateOct 27, 2021

Shortened course of radiation therapy offers similar long-term side effects following prostate removal surgery

A recent clinical trial found that a shortened course of radiation therapy after prostate removal surgery does not increase long-term side effects or lower quality of life compared to conventional treatment. Patients who underwent hypofractionated, post-operative radiation therapy experienced comparable genitourinary and gastrointestin...

UT Southwestern pioneers PULSAR-integrated radiotherapy with immunotherapy for improved tumor control

Researchers have developed a new adaptive radiotherapy strategy called PULSAR, which combines radiation and immunotherapy to improve tumor control. The approach uses artificial intelligence to personalize treatment plans, allowing oncologists to replan cancer treatment in under 30 minutes.

SourceUT Southwestern Medical Center·JournalInternational Journal of Radiation Oncology*Biology*Physics·DateAug 20, 2021

Pretreatment fatigue can mean worse survival outcomes for patients with cancer

Patients with cancer who experience clinically significant fatigue before treatment have shorter overall survival times and more side effects. Researchers analyzed four clinical trials testing lung and prostate cancer treatments, confirming that pretreatment fatigue may be an important prognostic factor in oncology.

SourceSWOG Cancer Research Network·JournalJCO Oncology Practice·TypeData/statistical analysis·DateJul 29, 2021

More collaboration between primary care and oncology may improve fragmented cancer care

Researchers conducted a randomized intervention that improved continuity of care and interprofessional collaboration between lung cancer patients and their family physicians. The bidirectional exchange of patient information and care summaries led to enhanced patient and family physician perceptions of care, resulting in better outcomes.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateMar 9, 2021

FDA Oncology Center of Excellence during COVID-19

The FDA Oncology Center of Excellence has developed initiatives to address the unique challenges faced by cancer patients during COVID-19. The center provides guidance and support to healthcare professionals, enabling them to provide high-quality cancer care despite the pandemic's impact.

SourceJAMA Network·JournalJAMA Oncology·DateDec 23, 2020

FDA support for oncology drug development during COVID-19

The FDA has issued guidance on clinical trials for cancer drug development during the COVID-19 pandemic. The guidance highlights regulatory challenges and lessons learned from recent experiences. By providing this support, the FDA aims to facilitate oncology drug development in a challenging environment.

SourceJAMA Network·JournalJAMA Oncology·DateOct 8, 2020

Enhanced reimbursement to oncology clinics increases prescriptions of evidence-based drugs

A pay-for-performance program increased prescriptions of high-quality, evidence-based cancer drugs by 5.1 percentage points without significantly changing total spending on care. The program improved the rate of high-value prescribing in oncology, leading to better patient outcomes and longer life expectancy.

SourceUniversity of Pennsylvania School of Medicine·JournalJournal of Clinical Oncology·DateOct 7, 2020

Breast cancer medication risk

A new study published in Frontiers In Oncology found a negative association between beta-blocker use and survival outcomes in patients with HER2 positive advanced breast cancer. The research highlights a subgroup of patients whose survival outcomes are poorer and calls for further investigation to improve treatment outcomes.

SourceFlinders University·JournalFrontiers in Oncology·DateSep 29, 2020

Genomic analysis predicts survival benefit of adjuvant chemotherapy following radiotherapy over radiotherapy alone in low-grade gliomas in NRG Oncology clinical trial

A clinical trial found that patients with IDH-mutant high-risk LGG, regardless of codeletion status, receive a survival benefit from adding postradiation chemotherapy. The study supports the use of WHO-defined molecular subgroups in predicting response to treatment.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateAug 31, 2020